DaVita Q2 FY2026: revenue up 5.2% to $3.55 billion, EPS $4.02
DaVita beat consensus earnings and grew revenue 5.2% to $3.55 billion, so our view is Bullish. The $4.02 per share came with a 16.3% operating margin and $490 million of operating cash flow, and full-year guidance implies a stronger second half. The caveats are a leveraged balance sheet and a book equity deficit, so the bullish case rests on cash generation rather than the balance sheet.
1 · Expected vs. Actual
Free preview belowDiluted EPS of $4.02 beat the $3.9212 consensus estimate and jumped from $2.58 a year earlier. Adjusted EPS equals GAAP EPS this quarter, so there are no add-backs doing the work. One caution: diluted shares fell to 66.1 million from 77.4 million, so buybacks are driving part of the per-share gain.
Revenue of $3.55 billion rose 5.2% from $3.38 billion in the same quarter last year. U.S. dialysis supplied $3.01 billion of that and other operating segments added $556.7 million before eliminations. Revenue per treatment slipped to $415.87 from $417.59 in the prior quarter, although it is up $14.33 on a year-to-date basis.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.